TABLE 4. Surveillance for acyclovir-resistant HSV in the immunocompromised population
| Variable tested |
Results in reference:
|
| 98 |
27 |
14 |
13 |
Abstracta |
|
| Prevalence of resistant HSV (%)b |
4.1 |
4.7 |
6.3 |
7.1 |
5.6 |
| No. of patients with resistant HSV/no. of patients tested |
3/74c |
7/148 |
6/95 |
14/196 |
12/216d |
| Period of surveillance |
Not specified |
Not specified |
1991-1993 |
1996-1999 |
1998-2000 |
| Location of survey |
United States |
United States |
United Kingdom |
France |
North America |
| Reason for immunodeficiency |
BMTe |
BMT, HIV, organ transplant, malignancy, high-dose steroids, neonate |
BMT, HIV, organ transplant, malignancy |
BMT |
HIV |
| Assay method |
Dye uptake |
Viral DNA inhibition |
Plaque reduction assay |
Dye uptake |
Plaque reduction assay |
|
a Gnann et al., Abstr. 38th Int. Conf. Dis. Soc. Am.
b Acyclovir-resistant HSV. With the exception of reference 27 and Gnann et al., data are from acyclovir-treated patients only.
c Acyclovir-resistant HSV was recovered from 1 of 52 patients during the initial treatment course and from 2 of 22 patients during treatment for second recurrences.
d Number of acyclovir-resistant HSV isolates/number of isolates tested. Multiple isolates from some patients were tested.
e BMT, bone marrow transplant recipient.
